Skip to main content

Advertisement

Table 3 Change of Cys C and GFR after EECP treatment (n = 30)

From: Effect of enhanced external counterpulsation treatment on renal function in cardiac patients

Characteristics Median (IQR)
Baseline End of 35thsession Follow-up
Estimated GFR    
GFR <60 mL/min/1.73 m2 (n = 12) n = 12 n = 9 n = 12
Cystatin C (mg/L) 1.55 1.44 1.4
  (1.26-1.85) (1.2-1.59) (1.14-1.65)
p-value   0.173 a 0.004 b **
GFR (mL/min per 1.73 m2) 43.59 46.11 47.52
  (39.1-53.29) (42.06-47.26) (41.1-55.76)
p-value   0.374 a 0.003 b **
GFR ≥60 mL/min/1.73 m2 (n = 18) n = 18 n = 18 n = 18
Cystatin C (mg/L) 0.83 0.82 0.8
  (0.73-0.89) (0.72-0.91) (0.63-0.92)
p-value   0.931 a 0.052 b
GFR (mL/min per 1.73 m2) 86.05 92.34 88.81
  (75.16-103.3) (83.46-105.38) (81.22-109.79)
p-value   0.157 a 0.124 b
NT-proBNP    
NT-proBNP ≤125 pg/mL (n = 9) n = 9 n = 9 n = 9
Cystatin C (mg/L) 0.78 0.82 0.81
  (0.76-0.87) (0.72-0.87) (0.77-0.87)
p-value   0.906 a 0.553 b
GFR (mL/min per 1.73 m2) 86.69 88.75 83.11
  (85.28-92.84) (83.46-105.23) (81.42-96.54)
p-value   0.374 a 0.767 b
NT-proBNP >125 pg/mL (n = 20) n = 20 n = 17 n = 20
Cystatin C (mg/L) 1.26 1.16 1.14
  (0.94-1.68) (0.84-1.53) (0.88-1.51)
p-value   0.523 a 0.001 b**
GFR (mL/min per 1.73 m2) 59.43 57.66 62.26
  (43.31-74.47) (46.11-91.46) (46.97-83.18)
p-value   0.246 a 0.001 b**
NT-proBNP decline >30% from baseline (n = 10 ) n = 10 n = 9 n = 10
Cystatin C (mg/L) 1.01 1.00 0.97
  (0.81-1.31) (0.77-1.2) (0.69-1.2)
p-value   0.594 a 0.017 b*
GFR (mL/min per 1.73 m2) 65.53 66.87 66.46
  (43.68-79.98) (47.26-93.98) (49.02-91.85)
p-value   0.214 a 0.051 b
  1. Values are Median (25th-75th percentile). p- value was calculated with the use of Wilcoxon signed ranks test, a End of 35th session versus baseline; b Last follow-up versus baseline.
  2. (*) indicated statistically significant p-value less than 0.05; (**) indicated statistically significant p-value less than 0.01.